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ABSTRAKT
Cílem diplomové práce je analýza aterosklerózy a její spojitost s kardiovaskulárním 
onemocněním. Také opatření proti rozvoji aterosklerotické léze a jejími následnými 
komplikacemi. Budou uvedeny aspekty, jako jsou diagnóza, patogeneze a změna 
endotelu, a s nimi spojené komplikace a klinické projevy. 
Budou analyzovány farmakologické látky/léčiva bránící rozvoji tohoto onemocnění s 
látkami/léčivy proti dyslipidémii – která je jedním z hlavních rizikových faktorů 
rozvoje aterosklerózy -  je centrem pozornosti tohoto příspěvku je.
V dalších kapitolách bude popsán nový pohled na prevenci a léčbu aterosklerózy 
používající statiny a fibráty, analýza výhod a toxicity jednotlivých statinů, a také 
možnosti přínosů a rizik při jejich kombinaci.
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ABSTRACT
The goal of this Thesis is to analyze atherosclerosis and its relationship to 
Cardiovascular Disease, as well as the measures taken to oppose the development of 
an atherosclerotic lesion and its following complications. Aspects such as Diagnosis, 
Pathogenesis and alteration of endothelium, as well as complications and clinical 
manifestations associated to them will be stated. 
Pharmacological agents opposing the development of this disease will be 
analyzed, with agents opposing dyslipidemia - one of the major risk factors of 
developing atherosclerosis – being the center of this paper’s focus.
In the next chapters, new insight on preventing and treating atherosclerosis using 
statins and fibrates, analysis of individual statins benefits and toxicities as well as 
possibilities of their combination benefits and risks will be brought to light.
6
TABLE OF CONTENTS
1 INTRODUCTION ............................................................................................................. 8
2 DEFINITION OF ATHEROSCLEROSIS ........................................................................ 9
3 HISTORY OF ATHEROSCLEROSIS ............................................................................. 9
4 EPIDEMIOLOGY ........................................................................................................... 10
5 ENDOTHELIUM ............................................................................................................ 10
5.1 Endothelial physiology............................................................................................ 10
5.2 Endothelial alteration............................................................................................... 11
6 DIAGNOSIS OF ATHEROSCLEROTIC CHANGES................................................... 11
7 PATHOPHYSIOLOGY OF ATHEROSCLEROTIC PLAQUE DEVELOPMENT ...... 12
8 RISK FACTORS ............................................................................................................. 14
8.1 Modifiable risk factors ............................................................................................ 14
8.2 Non-modifiable risk factors..................................................................................... 16
9 CLINICAL MANIFESTATIONS AND COMPLICATIONS RELATED TO 
ATHEROSCLEROTIC LESION ............................................................................................ 17
10 PREVENTION OF ATHEROSCLEROSIS................................................................ 18
10.1 Primary Prevention .................................................................................................. 18
10.2 Secondary prevention .............................................................................................. 19
11 GENERAL NON-PHARMACOLOGICAL TREATMENT ...................................... 20
12 GENERAL PHARMACOLOGICAL TREATMENT ................................................ 21
13 DEFINITION OF STATINS ....................................................................................... 24
14 STATIN USAGE IN ΤΗΕ PREVENTION OF ATHEROSCLEROSIS .................... 25
14.1 Statin usage in Primary Prevention of CVD............................................................ 25
14.2 Statin usage in Secondary Prevention of CVD........................................................ 25
15 STATIN USAGE IN THE TREATMENT OF ATHEROSCLEROTIC 
ALTERATIONS ..................................................................................................................... 26
16 DIFFERENCES BETWEEN INDIVIDUAL STATIN MEMBERS .......................... 28
17 PITAVASTATIN: A NEWER MEMBER WITH NEW BENEFITS......................... 29
18 OTHER USES OF STATINS ..................................................................................... 29
19 STATINS SIDE EFFECTS AND CONTRAINDICATIONS .................................... 31
20 DEFINITION OF FIBRATES .................................................................................... 33
21 FIBRATE USAGE IN THE PREVENTION AND TREATMENT OF 
ATHEROSCLEROTIC ALTERATIONS............................................................................... 34
22 FIBRATES ADVERSE EFFECTS AND CONTRAINDICATIONS ........................ 35
7
23 POSSIBILITIES OF STATIN AND FIBRATE COMBINATION-BENEFITS AND 
RISKS INCLUDED ................................................................................................................ 35
24 CONCLUSIONS ......................................................................................................... 37
25 REFERENCES ............................................................................................................ 39
8
1 INTRODUCTION
After the industrial revolution (18th to 19th century A.D.), an increase in many 
asymptomatic diseases was observed, primarily because of population lifestyle 
changes in the developed countries. Diabetes mellitus, arterial hypertension and 
atherosclerosis are some examples of diseases whose development is attributed to 
sedentary lifestyle in a major degree, although other risk factors that will be analyzed 
later on exist. 
This Thesis is focused on atherosclerosis and its development, as well as the 
treatment benefits with statins and fibrates, two of the most widely used medications 
for the treatment of the abnormalities leading to this particular lesion.
Atherosclerosis is a chronic vascular disorder developing in the endothelial 
intima. Many different factors including LDL cholesterol, smooth muscle cells, 
inflammatory mediators, receptors and calcium promote the building of a waxy and 
fatty mass called atherosclerotic plaque. 
Because of its nature of being an asymptomatic disease, atherosclerosis is usually 
in an advanced stage when diagnosed, and this is the reason why precaution 
measurements are the best way to counter this disease. Changes in lifestyle are of 
critical importance. Smoking cessation, increasing physical exercise, being cautious 
with lipid intake, body weight management, diabetes management and blood pressure 
control are some of the major modifiable risk factors that should be taken into 
account. (1)
Regarding Pharmacotherapy, many different agents may be used including 
statins, fibrates, vitamin B3, anion exchange resins and other agents that will be
analyzed later on in this Thesis.
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2 DEFINITION OF ATHEROSCLEROSIS
Atherosclerosis, a word having its origins in the Greek words “athere” (gruel), 
and “skleros” (hard), is the progressive buildup of cholesterol, inflammatory mediator 
cells, calcium, smooth muscle cells (SMC’s) and other substances in the endothelium 
of middle and large-sized arteries, causing a gradual hardening of the arteries, which 
in turn causes many different complications. These complications usually include 
Acute Myocardial Infarction, Ischemic Stroke and Peripheral Artery Disease. All of 
these complications arise from the complete occlusion of an artery due to elevated 
levels of the above-mentioned factors (lipids, SMC’s, calcium), which cause the 
formation of a thrombus. (2)
3 HISTORY OF ATHEROSCLEROSIS
Despite its popularity as a modern lifestyle disease, research has shown that 
Atherosclerosis was a common health issue for more than 4000 thousand years. 
Despite the fact that treatment for Atherosclerosis was available prior to statin 
discovery, there is no solid evidence of its effectiveness. Due to its nature, being an 
asymptomatic disease, the diagnosis usually took place after a complication had
already taken place, or after the subject was dead, making it extremely inefficient. As 
Endo et al reported, atherosclerosis started to become clinically significant for modern 
medicine in 1910, when Windaus first connected elevated cholesterol to the 
development of atherosclerotic lesions. In 1913, Anitschkow conducted experiments 
on animals (rabbits), feeding them foods rich in cholesterol. The result was the 
development of fatty deposits in the aortal endothelium, namely atherosclerosis, 
which led to CVD morbidity and mortality on the rabbits. After that, the matter of 
atherosclerosis took years to be focused on again, and it was not until 1939 when
Müller connected atherosclerotic lesion development risk to genetic predisposition. 
Later on, many scientists were involved into separating all these parameters following 
atherosclerosis (Low Density Lipoprotein, cholesterol biosynthesis, enzymatic 
involvement and drug development), and up to this date research continues to 
maximize drug efficacy and minimize involvement of risk. (3)
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4 EPIDEMIOLOGY
Atherosclerosis usually takes place in the latter stages of life, but the changes in 
arterial and blood physiology from adolescence and even childhood. The male gender 
is proved to have a higher risk of developing some type of atherosclerosis during their 
lifetime compared to females and this is both related to their lifestyle (alcohol abuse)
and hormonal physiology (testosterone vs. estrogen). (4)
5 ENDOTHELIUM
In 1865, Wilhem His first introduced the term “endothelium”, defining it as the 
cellular lining covering blood vessels, lymphatic vessels and mesothelial cavities. 
Later on, by the time electron microscope was introduced, a distinction regarding the 
vascular bed lining became possible. It was stated that the cells lining individual 
vascular trees were different in both structure and function from organ to organ and 
from cavity to cavity. (5)
5.1 Endothelial physiology
The endothelial physiology plays an important role in many functions of an 
organism, such as inflammation, oxygen supply, synthesis and migration of cells into 
the tissue, as well as metabolism of many different substances, according to the 
stimulus it receives. Vasomotor functions (vasodilatation, vasoconstriction) are 
regulated by the endothelium, through the production of certain substances. 
Endothelium is also responsible for many hemodynamic effects, (blood pressure and
blood flow) regulated through vasodilatation and vasoconstriction, as well as through 
oncotic and hydrostatic pressures. Regulation of coagulation can also be 
accomplished through the endothelium, since it is able to produce substances 
responsible for blood-clotting and blood-thinning. One of the most important parts of 
the endothelial physiology regarding atherosclerotic lesion development, though, is its 
ability to maintain an inhibitory activity towards oxidative stress, since, as we will see 
in the next chapters, is a major cause of its formation through Low Density 
Lipoprotein (LDL) β-oxidation. (5)
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5.2 Endothelial alteration
When altered, this physiology has many effects primarily on cardiovascular disease 
development and together with other risk factors such as arterial hypertension, 
Diabetes Mellitus, Dyslipidemia, smoking and sedentary lifestyle, the process is 
accelerated. In 1973, Bevilacqua et al. suggested that endothelial cell dysfunction is 
because the endothelium becomes hyperadhesive to platelet cells. Focusing on the 
endothelial dysfunction relation to atherosclerosis, it is confirmed that its homeostatic 
functional alterations (vasoconstriction, coagulation, oxidation, inflammation), can
cause disease complications such as Acute Myocardial Infarction, (A.M.I.), stroke and 
other general thromboembolic and metabolic disorders. These alterations start with 
accumulation of lipids, (primarily low density lipoprotein) and sensitivity to fat 
oxidation (a process known as oxidative stress). (6) 
6 DIAGNOSIS OF ATHEROSCLEROTIC CHANGES
There are several ways to diagnose a potentially dysfunctional endothelium. 
National Heart, Lung and Blood Institute suggests several ways of diagnosing 
atherosclerosis. Angiography is a method in which a catheter is inserted in a patient’s 
arm, thigh or neck, infusing a dye. This dye is able to show blood circulation through 
the vascular tree, and the examination takes place with a chest X-ray. By evaluating 
the X-ray, the physician can observe any arterial stenosis, of which the most common 
cause is atherosclerosis. Electrocardiogram (EKG) is another method of diagnosing 
changes occurring because of cardiac damage. In EKG, measurements of cardiac 
electrical activity, heart rate and heart rhythm are accomplished painlessly. Abnormal 
EKG results may indicate damage caused by atherosclerotic vessel stenosis. 
Stress echocardiography is a diagnostic method that uses physical heart exercise, 
or if that is not possible a β1-receptor agonist (Dobutamine), to induce cardiac work. 
Through echocardiography, a physician can observe cardiac wall abnormalities in 
rhythm and contractility, as well as abnormal blood flow through the chambers, which 
may indicate cardiac damage because of stenosis or occlusion. Stress 
echocardiography is one of the most common methods of diagnosing cardiac 
abnormalities, because of its non-invasive nature. (7)
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Computed Tomography scanning (CT-scan), is a method able to diagnose 
significantly stenosed or obstructed coronary arteries (see figure 1), resulting in the 
diagnosis of atherosclerotic lesion. (8)
Figure 1: Coronary artery Computed Tomography scan, showing stenosis caused by
non-calcified atheromatous plaque in the mid-left anterior descending coronary artery.
http://circ.ahajournals.org/content/129/12/1341/F2.large.jpg,11/4/2015
7 PATHOPHYSIOLOGY OF ATHEROSCLEROTIC PLAQUE 
DEVELOPMENT
Atherosclerosis is a multi-step disease and its development starts in the 
endothelium. Development of atherosclerotic changes occurs systematically, when 
abnormal endothelial functions accumulate.
The first step begins when monocytes adhere to the endothelium, causing their
migration through the membrane into the tunica intima. (Figure 2,b) Monocytes then 
mature to become macrophages, which start storing lipids coming from β-oxidation of 
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Low Density Lipoprotein (LDL), forming Foam cells. This process slowly decreases 
the endothelial function, which combined with the inflammatory mediator 
dysfunction, namely macrophages, results in the formation of fatty streaks. (9)
The second step includes the migration of smooth muscle cells from tunica
media, as well as an extended accumulation of smooth muscle cells already existing in 
intima. The accumulated smooth muscle cells then proliferate, with the concomitant 
accelerated production of collagen, elastin and proteoglycans. (Figure 2,c) Following 
these processes is the accumulation of fat derived from the apoptosis of macrophages 
and smooth muscle cells, creating a mass known as the lipid or necrotic core. (9)
The last step comprises of extended deposition of calcium, cholesterol and 
necrotic cells into the surface of the lipid core leading to the formation known as the 
atherosclerotic plaque. In the surface of this plaque, a continuous accumulation of 
collagen, elastin and smooth muscle cells form a layer called “fibromuscular cap”. 
The thickness of this layer is connected to the stability of the atherosclerotic plaque, 
meaning the thinner the cap is, the more susceptible it is to rupture and a potential 
vessel thromboembolism (Figure 2,d). (9)
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Some conditions/states of the human organism tend to accelerate formation of 
any type of atherosclerotic lesion, such as Coronary or Peripheral Artery Disease. 
These states usually include arterial hypertension, Dyslipidemia, smoking, Diabetes 
Mellitus type II, age, gender and genetics and I. Risk factors can be categorized 
according to their modification potential in modifiable and non-modifiable. (10)
8.1 Modifiable risk factors
This type of risk factors is mostly present because of sedentary lifestyle, improper 
caloric quality and quantity consumption and lack of exercise. 
Arterial Hypertension is one of the major causes of endothelial dysfunction, 
promoting vascular inflammation, oxidative stress and loss of vascular elasticity. 
Combined with a gradual drop in Nitric Oxide bioavailability, which is responsible 
for vascular dilatation, it results in functional change of the smooth muscle cells lining 
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the endothelium, causing vasoconstriction, LDL β-oxidation, inflammatory mediator 
arrival at the damaged lining, and the whole cascade forming the fibromuscular cap. 
(5)
Diabetes Mellitus is a pathological condition characterized by abnormal elevated 
glucose levels freely circulating the bloodstream, namely hyperglycemia. In Diabetes, 
lack of insulin (type I), or insulin resistance (type II), leads to a loss of endothelial 
functionality. Small blood vessels are affected first, which is why Diabetic 
Retinopathy and Nephropathy are common as complications of Diabetes. Damaged 
blood vessels are susceptible to inflammation, loss of elasticity and vascular tone, all 
of which are major risk factors of atherosclerosis. (5)
Smoking is a well-known risk factor for the development of many diseases, 
including atherosclerosis. Nicotine, a substance present in tobacco, infiltrates the 
blood stream, decreasing Nitric Oxide (NO) production and bioavailability, resulting 
in gradual vasoconstriction. In addition, nicotine is responsible for vascular spasm 
generation, as well as morphological and functional change in the endothelial lining. 
This results in elevated platelet adhesion on the endothelial surface, which may lead 
to formation of thrombus. (5)
Dyslipidemia, the last major modifiable risk factor for the development of 
atherosclerosis, describes a pathologic condition in which one or more lipoprotein is 
elevated or decreased. This can be attributed to genetic deficiencies or mutations 
caused by lack of exercise and saturated or trans-unsaturated fatty acid chronic intake. 
Dyslipidemia can be analyzed into several types, the most risky of which (in the 
development of atherosclerosis) is familial hypercholesterolemia. In this type of 
dyslipidemia, a decrease in the expression of LDL-R receptors leads to elevated 
circulating LDL, increasing the risk of β-oxidation and its following accumulation in 
the damaged vessel as foam cell. (11)
C-Reactive Protein (CRP) is a protein playing a role in inflammatory response. 
Its usual levels differ among different races and different health states, but should be 
in the range of 1-2.6 mg/L in a healthy individual. Elevated CRP suggests an 
atherogenic risk factor, since inflammatory response is one of the key factors for the 
pathogenesis of some atherosclerotic lesion. Other modifiable risk factors include 
obesity, sedentary lifestyle, lack of physical activity, stress and alcohol consumption. 
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Reducing or modifying these risk factors is critically importance to counter this 
disease. (12)
8.2 Non-modifiable risk factors
There are, however, risk factors for developing some type of atherosclerotic 
disease, which are not related to lifestyle. Age, gender and Genetic Predisposition are 
examples of risk factors that cannot be treated or manipulated by any means of 
pharmacotherapy or lifestyle change.
Aging is a natural process affecting each living organism, and hence, humans. As 
the age of a person increases, the endothelium becomes more and more susceptible to 
elasticity loss, NO bioavailability, oxidative stress and inflammation sensitivity, 
vasoconstriction and other vascular pathologic conditions. These abnormalities start to 
accumulate and at some point, irreversible endothelial damage leads to 
atherosclerosis, which in turn may affect every organ (kidney, brain, heart, lungs, eyes 
and bones). (5)
Gender is a risk factor by itself. Males are more susceptible to developing 
atherosclerotic lesion sometime in their life than females, and this can be explained by 
differences in hormonal nature and regulation between the two sexes. Premenopausal 
women are somewhat protected from Cardiovascular Disease (CVD) development, 
mainly because of the estrogen’s effect on lipid profile and vasculature. 
Vasoconstrictors such as serotonin and angiotensin are also regulated through an 
estrogen-regulation pathway, leading to equilibrium between vasoconstrictor and 
vasodilator agents in women. After menopause, though, estrogen levels are highly 
depleted, leading to a multifold risk increase in developing CVD. In males, on the 
other hand, androgen levels decline with age, gradually and steadily decreasing as 
men grow older. Androgen depletion leads to numerous endothelial dysfunction 
effects, such as inflammation, disrupted lipid tolerance, changes in smooth muscle 
morphology as well as vasoconstriction and arterial hypertension. (13)
Genetic Predisposition plays a key role in the development of atherosclerosis and its 
complications. Mutations in physiological morphology and functionality of 
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endothelium as well as of some atherogenic substances (LDL) increase the probability 
of atherosclerotic lesion formation. There are types of dyslipidemias caused by 
genetic defects, such as familial hypercholesterolemia, causing an accelerated CVD 
development. History of atherosclerosis in the family usually suggests extra attention 
in these patients. Genetic predisposition is crucial to atherosclerosis prevention and 
care. (11)
9 CLINICAL MANIFESTATIONS AND COMPLICATIONS 
RELATED TO ATHEROSCLEROTIC LESION
Atherosclerosis is generally an asymptomatic disease especially in the early 
stages of development. However, if sufficient stenosis occurs, atherosclerosis is 
manifested as “angina pectoris”, a term originating from the Greek word γχόνη 
ankhonē ("strangling"), and the Latin word pectus ("chest") which is used in medicine 
to describe deep, heavy and pressure generating chest pain. Updated on July 30, 2014, 
American Heart Association (AHA) describes angina as chest pain caused by cardiac 
muscle hypoxia, meaning that cardiac oxygen demands exceed oxygen supply. We 
must state that chest pain is a symptom, which means the underlying cause may be 
caused by some other disease like peptic ulcer. 
AHA describes four types of angina pectoris with different clinical 
manifestations and risks for complications.
The most common type is the so-called stable or effort angina, in which the pain 
is manifested when a person is working out or during stress and/or anxiety.
Variant (also known as Prinzmetal or Vasospastic) angina is another type of 
angina pectoris clinically manifested as deep pain due to coronary vessel spasm. This 
spasm is usually related to exposure to cold, drug use and smoking and the pain 
attacks often take place during early hours. 
The most dangerous type regarding risk of complication is the condition called 
unstable angina, and it can occur at any time, even when lying down or resting. In 
unstable angina, the patient feels extended discomfort, and the pain can lead to a 
series of thromboembolisms. The embolus is formed by the rupture of an unstable 
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atherosclerotic plaque, resulting in Acute Myocardial Infarction (AMI), stroke, or 
peripheral ischemia.
Peripheral artery disease (PAD) is also related to atherosclerosis and the place of the 
blood clot reflects the place of ischemia. This disease can lead to ischemia of many 
different organs (eyes, kidneys, intestines, sex organs, extremities etc.) causing 
blindness, kidney failure or erectile dysfunction. A series of complications due to 
PAD can result from Carotid artery disease. Carotid is the artery supplying the brain 
with oxygen and its stenosis or blockage can cause ischemic brain stroke, a common 
condition, especially in the elderly, causing disability in many patients. PAD is a risk 
factor of CVD development by itself, since a thrombus formation in the periphery can 
migrate and become an embolus in the coronary arteries, leading to Acute Myocardial 
Infarction (AMI). (14)
10 PREVENTION OF ATHEROSCLEROSIS
Primarily, health care providers tend to try to deal with asymptomatic diseases 
before a complication takes place. This is the main reason why prevention of 
atherosclerosis is critical at this point. In most people, the process of arterial 
hardening is already taking effect in their early adulthood. Generally speaking, there 
are three different approaches when discussing about prevention of atherosclerosis, 
namely Primary, Secondary and Tertiary.
10.1 Primary Prevention
In primary prevention, the goal is to control the modifiable risk factors of 
atherosclerosis development. Non-modifiable risk factors (family history, sex, 
genetics, age) can also be present, but as their name suggests, there is little to be done 
to affect them. Lifestyle changes can become the most effective treatment. Waking up 
early, quitting smoking, avoiding psychological stress, exercising, controlling lipid 
and carbohydrate consumption are some examples crucial in the primary prevention 
of atherosclerosis. As we will see in the next chapters, both pharmacological and non-
pharmacological treatment can affect the levels of these factors (omega-3 fatty acids, 
antioxidant substances, drugs etc.) (15)
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10.2 Secondary prevention
After the risk factors (hypertension, diabetes, dyslipidemia) appear, secondary 
prevention is on the table. In secondary prevention, risk factors of cardiovascular 
disease are present, but a complication has yet to appear. In addition to lifestyle 
changes, pharmacotherapy is usually very helpful in the treatment. Decreasing lipids, 
carbohydrates, thrombotic factors and inflammatory mediators circulating in the blood 
is of prior importance. Many different drugs affecting the levels of these factors are 
used to restore the healthy cardiovascular function. (14)
Arterial stress due to hypertension is a leading cause of atherosclerosis. 
Controlling arterial blood pressure, especially diastolic, being the pressure responsible 
for cardiac circulation and naturally affecting coronary vessels, is a good way to 
prevent the development of an arterial atherosclerotic lesion. To prevent 
atherosclerosis development, agents reducing blood pressure are advised. Obesity is 
another risk factor responsible for the disease development. In obese people, typical 
cardiovascular functions are burdened by the excess of fat tissue through the body and 
this stress can affect arterial hardening. Weight control is crucial at this point, before 
drug interventions occur. A change in diet and sedentary lifestyle can benefit a 
patient’s lipid and carbohydrate profiles, greatly reducing the risk of developing 
atherosclerosis. Dyslipidemia, a general term including many lipid profile 
abnormality possibilities as we have already stated, can be controlled by many agents, 
as we will suggest in the next chapters. (15) 
To oppose inflammatory response caused in atherosclerotic lesions, a number of 
anti-aggregation agents (e.g. acetylsalicylic acid, clopidogrel) are commonly used to 
protect cardiac function. (16) 
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11 GENERAL NON-PHARMACOLOGICAL TREATMENT
Atherosclerosis can be developed due to many risk factors such as hypertension, 
Diabetes Mellitus, dyslipidemias, cigarette smoking, sedentary lifestyle and quality of 
food consumed. However, the atherosclerotic changes in the endothelium might start 
occurring in late adolescence or early adulthood. This is why health care institutes and 
health care providers suggest that the best way to prevent and minimize the risk of 
developing atherosclerosis and its following complications is to follow a healthy 
lifestyle, which includes cessation of bad habits, exercising, and knowledge of daily 
caloric quality and quantity intake. (5)
To normalize lipid levels in the blood, omega-3 (ω-3) polyunsaturated fatty acid 
(PUFA) intake is recommended. Morphology of the fatty acids seems to play a major 
role in atherogenesis, as seemingly trans- fatty acids tend to be atherogenic, while cis-
fatty acids do not. According to new insight on their mechanism of action, this type of 
PUFA decreases many atherogenic pathological conditions, such as hypertension, 
hypertriglyceridemia, cardiac arrhythmias, insulin sensitivity modulation, oxidative 
stress development as well as inflammatory expression in the endothelium. (5,17) 
Alcohol has a positive lipid profile when consumed moderately (e.g. a glass of 
wine 5 times per week). Together with other constituents, like polyphenol compounds 
found in red wine, it has the ability to gradually normalize lipid profiles, by increasing 
HDL decreasing LDL. These effects are clinically significant only in red wine 
consumption (Huang et al). Antioxidant, antithrombotic and anti-inflammatory and 
angiogenic properties of alcohol may decrease the overall risk of atherosclerotic 
lesion development. Excessive alcohol intake, on the other hand, is associated with an 
increased risk of Cardiovascular and Hepatic disorders, because of its adverse effects 
(hypoglycemia, myopathy, gastrotoxicity, cardiac arrhythmias, hypovitaminosis). 
(5,18)
Antioxidant agents include Vitamins C (Ascorbic acid) and E (Alpha-
Tocopherol), substances naturally occurring in some foods like Orange (Vitamin C) 
and wheat or sunflower oil (Vitamin E). Melatonin, an endogenous hormone naturally 
affecting sleep pattern, also has antioxidant, antihypertensive and anti-inflammatory 
effects. (5)
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Regular physical activity is the key to prevent atherosclerosis. In combination 
with dietary changes, it can help reduce risk factor development (dyslipidemias, 
diabetes, hypertension) while keeping the cardiovascular system in a state of balance. 
The duration and intensity of the exercise should be managed according to a patient’s 
co-morbidity states, age, gender and other risk factors. Chronic moderate exercise has 
evidence of reducing risk of cardiovascular disease, as it has positive effects on 
Peripheral Vascular Resistance (PVR) and physiological endothelial function 
restoration. (5)
According to World Health Organization (WHO), smoking is related to the 
development of at least 10% of all cardiovascular disease reported cases. Smoking has 
a complete negative effect on many levels. A gradual increase in LDL and decrease in 
HDL was first reported in 1989 (Craig et al). Further clinical studies up to the present 
day support these results. Nicotine and other carcinogenic substances contained in the 
smoke increase blood viscosity and thrombophilia by increasing fibrinogen and 
homocysteine levels. Smoking also causes vasoconstriction through a NO decreasing 
mechanism, which is very risky especially in patients already having a narrowed 
artery. One of the major controversial and ethical issues of non-smokers is the so-
called passive smoking, which is as harmful as normal smoking, but can be even more 
harmful in groups like children and the elderly, or other groups suffering morbidities 
like asthma or Chronic Obstructive Pulmonary Disease (COPD). (5,19)
12 GENERAL PHARMACOLOGICAL TREATMENT
Many kinds of different pharmacological agents are used to treat risk factors of 
atherosclerosis and the complications that rise from this type of lesion. Agents acting
against cholesterol and LDL formation, platelet aggregation and blood coagulation 
antagonists are often used. 
Treatment of risk factors for atherosclerosis is the best way to minimize the risk 
of atherosclerotic lesion development, and that is, in fact, the main focus of 
pharmaceutical interventions regarding patients already diagnosed with one or more 
risk factors. Dyslipidemias are usually managed by lipid-lowering agents. Statins are
agents inhibiting 3-hydroxy-3-methylglutaryl Coenzyme A, an enzyme responsible 
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for the last step of cholesterol synthesis. They are widely used to produce a 
cholesterol lowering effect and are often used in many heart disease and stroke 
prevention strategies. As we will further analyze, statins are usually the drug of choice 
in many anti-atherosclerotic measurements taken in patients at risk. (20)
In dyslipidemias, other kinds of drugs are used to lower and control cholesterol 
levels. One of these kinds are the Fibrates, a group of agents indirectly inducing LDL 
lipolysis through peroxisome proliferator activated receptor α (PPARα) agonism, and
ultimately decreasing triglyceride levels circulating in the blood. (21) 
Vitamin B3 or Niacin is an essential vitamin for the preservation of the human 
organism and responsible for some of its vital functions, being a precursor of 
Nicotinamide Adenine Dinucleotide Phosphate (NADP), and its protonated form 
(NADPH). These cofactors play a major role in catalyzing many biochemical 
metabolizing processes, such as fatty acid and cholesterol regulation. Elevated levels 
of niacin have evidence of lowering circulating LDL, but more importantly, elevating 
HDL levels, which is essential for better cholesterol utilization by the body. (22)
Drugs having the ability to bind bile acids in the intestinal tract, namely bile acid 
sequestering agents (Cholestyramine, Colesevelam, Colestipol), are sometimes used 
to lower circulating cholesterol in the blood, especially in combination with statins, 
fibrates and Niacin. Their ability to block enterohepatic bile acid recirculation has a 
negative feedback in hepatic cholesterol production. A homeostatic mechanism of the 
organism including HMG-CoA reductase tends to replenish the diminished 
cholesterol levels and therefore a combination of bile acid sequestrant drugs with 
HMG-CoA reductase inhibitors is usually advised to avoid this mechanism. Because 
of their high drug-drug interaction activity, these agents should be administered with 
time intervals before or after sequestering drug administration. (23,24)
Cholesterol is normally absorbed in the small intestine. Ezetimibe is an agent 
responsible for inhibiting the absorption of cholesterol by the small intestine and 
therefor increasing uptake and utilization of circulating cholesterol, resulting in an 
overall decrease in the cholesterol levels in the blood. (25)
Agents acting against platelet aggregation are a common action taken to prevent
atherosclerosis formation and complications. Acetylsalicylic acid (Aspirin), is 
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commonly used in the low dose of 100mg once daily, to prevent atherosclerosis 
inducing aggregation and thromboembolism. The mechanism of action of aspirin is 
the acetylation of Cyclooxygenase-1 (COX-1), followed by inhibition of the 
substrate’s (arachidonic acid) binding to cyclooxygenase. The result is the overall 
inhibition of the platelet aggregation pathway, followed by the inability of the blood 
to produce thromboxane. This results in a beneficial overall effect in the reduction of 
vasculopathies, especially if the patient is suffering with co-morbidities (Diabetes 
Mellitus, Hypertension, Dyslipidemias). As stated in ASTERIX and OBERON 
studies there is a 71% and 85% relative reduction in peptic ulcer formation
respectively. Peptic ulcer develops due to a COX-1 inhibition mechanism, when 
aspirin is combined with a proton pump inhibitor agent (esomeprazole in ASTERIX 
and OBERON study). (26,27)
Clopidogrel is an agent affecting ADP (adenosine diphosphate) dependent 
response pathway, by producing an irreversible inhibition to its binding to the platelet 
receptor (P2Y12). This causes a blockage in some essential functions resulting in the 
formation of fibrin. Fibrin is an essential component of the thrombus formation and its 
inhibition leads to a safe measurement taken against atherosclerotic lesions and the 
complications due to them. The strength of Clopidogrel is typically 75mg od, 
although it can be up to 325mg od. (26)
New P2Y12 inhibitors include Prasugrel, a thienopyridine agent producing a more 
potent and faster effect, but at the same time a higher gastrotoxicity, as shown in the 
TRITON study. (26,28) Ticagrelor, another agent inhibiting P2Y12 receptor, though a 
non-thienopyridine, shows a distinct faster response in onset of its action and potency 
when compared to Clopidogrel. According to the third phase of PLATO study, 
Ticagrelor shows much better benefit in mortality due to platelet aggregation related 
diseases such as atherosclerosis than Clopidogrel. (26,28) Elinogrel is a non-
thienopyridine agent with the same mechanism of action as Clopidogrel, except the 
fact that Elinogrel’s receptor inhibition is reversible and direct. It can be administered 
intravenously in addition to orally. (26) Cangrelor is the last new agent worth 
mentioning, because of its ability to resist enzymatic inactivation, and its usual 
intravenous application. (28)
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Anticoagulant drugs are also used to deal with atherosclerotic lesion 
complications. They are widely used especially in the secondary and tertiary 
prevention of complications due to atherosclerosis (stroke, AMI). Warfarin is an oral 
anticoagulant that was firstly used as a pesticide before the 1950s, but later on its 
anticoagulant activity was founded, making it the most common anticoagulant agent 
to this day. Commonly used in vasculopathies including thrombus formation like deep 
vein thrombosis and atherosclerosis, Warfarin is responsible for Vitamin K inhibition. 
Vitamin K is utilized by the human organism to produce many clotting factors, and its 
inhibition eventually leads to blood-thinning. Because of the increased risk of 
bleeding when administering warfarin, International Normalized Ratio (INR) is 
measured to ensure a safe course of treatment. (29,30)
New anticoagulant agents include different mechanisms of anticoagulant action. 
Direct thrombin inhibitors (Dabigatran) inhibit thrombin, a protease responsible for 
the formation of Fibrin through Fibrinogen, a component necessary for the formation 
of thrombus. Apixaban and Rivaroxaban are another class of new anticoagulant 
agents, and act by direct inhibition of factor Xa, the enzyme responsible for the 
formation of thrombin. (30)
13 DEFINITION OF STATINS
One of the major reasons why atherosclerosis develops is because of high levels of 
LDL cholesterol in the bloodstream. Cholesterol is produced by the liver, but before 
its production many different reactions with many substrates and enzymes must take 
place. Cholesterol is produced via a complex pathway including biotransformation of 
3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) into Mevalonate (a precursor 
of cholesterol) through the enzyme HMG-CoA Reductase. Statins are organic 
derivatives of fungi and act by inhibiting the enzyme HMG-CoA reductase. This 
happens through their binding to the enzyme, not letting the substrate (HMG-CoA) 
bind to its natural enzymatic binding site. At the same time, statins have the ability to
increase the number of LDL-binding receptors in the liver. A modest decrease in the
levels of LDL cholesterol is produced, while HDL levels are slightly heightened. (31)
Statins are a drug category consisting of many different agents that have distinct 
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effects on LDL, while milder effects on HDL and TAG levels. A number of statins 
have been distinguished, with differences in pharmacokinetics, strength (5-80mg), 
albumin-binding degree, first-pass effect and potency, namely: Atorvastatin, 
Cerivastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin and 
Simvastatin.
14 STATIN USAGE IN ΤΗΕ PREVENTION OF 
ATHEROSCLEROSIS
14.1 Statin usage in Primary Prevention of CVD
Statins are commonly used to prevent formation of atherosclerotic plaque in 
endothelial intima. In primary prevention of CVD, statins are commonly used.  The 
JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin) study was conducted in people with elevated hs-CRP (high 
sensitivity C-Reactive Protein) and Low Density Lipoprotein levels that were lower 
than 7,2 mmol/l. The results were inconclusive regarding rosuvastatin’s comparison to 
other medical interventions devoted to primary prevention of CVD. However, a 
general decrease in the risk of developing some kind of CVD complication was noted
with rosuvastatin treatment versus the placebo groups. (12,32) 
It is well-known nowadays that prescription of statins for primary prevention of CVD 
must be adjusted to each patient individually according to their degree of risk of 
developing CVD. Many organizations such as American Heart Association (AHA) 
approve the use of statins on patients at high risk of developing CVD. Generally 
speaking, the combination of statins with non-pharmacological treatment strategies
such as lifestyle changes is crucial at this stage. (32,33)
14.2 Statin usage in Secondary Prevention of CVD
In secondary prevention of CVD, statin therapy is focused on the urgent necessity of 
lowering LDL cholesterol as well as CRP. Given to patients already suffering a risk 
factor of atherosclerotic plaque development, statins have shown promising results in 
reduction of LDL and CRP, having as a starting phase the results of the JUPITER 
study. Combined with their antithrombotic and anti-inflammatory effects, the 
resulting treatment is evident to lower morbidity and mortality due to atherosclerosis-
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related complications (stroke, AMI). Patients suffering with Diabetes Mellitus have a 
significantly accelerated atherosclerotic lesion development since in Diabetes elevated 
glucose negatively affects the vascular system in many levels (elasticity, PVR, insulin 
receptor depletion, insulin resistance). Other morbidities like Peripheral Artery 
Disease are on the focus of secondary prevention of CVD and evidence including 
many clinical trials show benefit in statin usage. (5,32,34,35)
15 STATIN USAGE IN THE TREATMENT OF 
ATHEROSCLEROTIC ALTERATIONS
Treating a developed atherosclerotic lesion must be focused on management of 
pathophysiology that led to it. Management of hypercholesterolemia is crucial 
especially in the beginning of the treatment. Statins, as we have already described, 
have the ability to decrease cholesterol synthesis as well as increase LDL receptors in 
the liver, inducing LDL binding and utilization and at the same time decreasing LDL 
production. Despite their moderate LDL-lowering and mild HDL-increasing effects, 
research has shown that they help in the process of plaque dispersion and 
consequently gradual reversion of atherosclerosis. Their anti-inflammatory effect 
firstly became clinically important after the JUPITER study with hs-CRP. It is now 
known that the anti-inflammatory mechanism of statins begins in the cholesterol 
formation pathway. A process known as protein (iso)prenylation (see Figure 3), 
taking effect by products of mevalonate (a precursor of cholesterol), namely Farnesyl 
PyroPhosphate (FPP) and GeranylGeranylPyrophosphate (GGPP), is found to be 
responsible for many atherogenic processes including pro-inflammatory cytokines and 
signal transduction across the Cardiovascular System (CVS). Statins have the unique 
effect of inhibiting protein (iso)prenylation, which leads to a decrease in all these 
atherogenic inflammatory response processes across the CVS. In addition, statins are 
effective against oxidation stress caused by oxidized LDL (ox-LDL), as well as on
NO synthesis in the vascular endothelium, which in turn helps in vasodilatation and 
alleviation of hypertension. A complete disease reversion has yet to be found but 
statins are the drug of choice at this point. (31,34,36)
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Figure 3: The mechanism of action of statins and how it affects protein prenylation.
http://www.biolreprod.org/content/75/1/107/F5.large.jpg 26/4/2015
Leaving these effects aside, statins have mild endothelial activity. They are 
thought to reverse and restore endothelial physiological function and elasticity and 
reverse inflammation caused in tunica intima. When physiological endothelial 
function is restored, diminished levels of LDL in the liver cause an increase in the 
production of LDL receptors by the endothelium. The overall effect is increased 
uptake of LDL by the receptors, diminished LDL levels in the circulation, and an 
increase in quality of circulating agents. (34,36)
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16 DIFFERENCES BETWEEN INDIVIDUAL STATIN 
MEMBERS
While they all have the same mode of action on cholesterol lowering, statins 
differ in potency, lipophilicity, degree of cholesterol decreasing effect, side effect 
intensity, drug-drug and drug-food interaction extent.  Atorvastatin, Pitavastatin, 
Simvastatin, Fluvastatin and Lovastatin tend to be more lipophilic while Rosuvastatin 
and Pravastatin are hydrophilic. (37)
Their pharmacokinetics also play an important role in their absorption, 
distribution, metabolism and excretion from the body. Lovastatin and Simvastatin
become active in their lactone form while Atorvastatin is active as a calcium 
trihydrate salt. There are also differences in their risk of side effect expression. For 
example, Cerivastatin has been withdrawn from the market in 2001 because of many 
cases of myositis and rhabdomyolysis in patients that received this agent. (37)
Regarding their potency, Atorvastatin and Rosuvastatin are the most potent 
agents that competitively inhibit HMG-CoA reductase, resulting in the most distinct 
LDL-lowering effect. Simvastatin and Pravastatin show moderate inhibiting potency, 
and moderate LDL-lowering effect. Correct agent and dose administration is possible, 
taking of course into account the individual patients’ other risk factors, co-
administered drugs and co-morbidities together with atherosclerotic disease. (33,37)
Leaving Pravastatin aside, all other statins extensively bind to albumin, making it 
less likely to displace other co-administered agents. Some of these agents 
(Simvastatin, Lovastatin) are prodrugs, and there is a delay in their starting time of 
action because they first need to be hydrolyzed to their active form. First-pass effect is 
of great significance to drug interactions that may arise, especially when taking into 
account the CYP-450 (Cytochrome P-450) metabolizing system, the metabolizing 
activity of which may be induced or inhibited by other agents. Pravastatin is the only 
statin that can produce active derivatives in the stomach and not metabolized by this 
system. (37,38)
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17 PITAVASTATIN: A NEWER MEMBER WITH NEW 
BENEFITS
Focusing on its pharmacokinetics, Pitavastatin is greatly less affected by the 
CYP-450 metabolizing pathway in comparison with the rest of statin agents, making 
it less prone to develop drug-drug interaction induced toxicity and adverse effects. 
(37,39)
Many studies conducted in Europe and Asia showed the beneficial aspects of 
Pitavastatin over other statins. In Chiba study (Japan), a noticeable benefit of 
Pitavastatin in LDL cholesterol reduction resulted when compared to Atorvastatin. 
Many other comparative studies were conducted, and although some of them were 
inconclusive, most of them indicated benefits of Pitavastatin over other statins. Sasaki 
et al noted that these benefits included not only significant LDL reduction, but also 
significantly less adverse drug reactions mainly due to its non CYP-450 dependent 
metabolizing pathway. Despite its low dosage strength (1 to 4mg per dose), 
Pitavastatin has shown remarkable long-term improving outcomes regarding HDL 
cholesterol. Masana et al stated that as shown in the VOYAGER and PIAT studies 
there is a crucial benefit in patients suffering with Diabetes Mellitus, since there is a 
typical decrease in HDL due to impaired Lipoprotein Lipase activity in these patients. 
(39,40,41)
18 OTHER USES OF STATINS
Despite of their general usage for prevention and treatment of atherosclerosis, 
statins show promise when used to prevent complications of some other co-
morbidities existing together with atherosclerotic lesions. High glucose levels in the 
bloodstream present in diabetic patients tend to damage blood vessels (especially the 
smaller ones), and this effects tends to accelerate the risk of developing an 
atherosclerotic lesion. Statins are helpful because of their ability to stop and even 
reverse inflammation of the endothelium to some degree.
Research has shown that statins may also be safely used to treat non-alcoholic 
fatty liver disease (NAFLD). This disease is characterized by excessive liver steatosis. 
Fat deposits replace the healthy hepatic tissue, and gradually decrease its 
functionality. This excess in fat deposits increases the risk of cardiovascular disease 
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because of plaque formation, and statins are beneficial at this point, reducing the risk 
of development of some complications because of atherosclerosis. Chatrath et al 
describes that according to a Greek study called GREACE (Greek Atorvastatin and 
Coronary heart disease Evaluation), there was a significant (68%) reduction in the risk 
of developing CVD in patients suspected of having NAFLD. (42)
A very interesting review has shown that beside their lipid-lowering ability, 
statins have systemic anti-inflammatory and immunity modulating effect. The 
mechanism of action includes immunomodulation of T-lymphocytes and endothelial 
progenitor stem cells, resulting in a positive endothelial effect. This effect takes place 
in hours, in contrast with the lipid-lowering effect showing results weeks after the first 
statin administration. Antonopoulos et al suggested that these effects are linked to a 
beneficial outcome when general inflammatory diseases such as Rheumatoid Arthritis
(RA) are concerned. Data received from studies such as TARA (Trial of Atorvastatin 
on Rheumatoid Arthritis) suggest that there is an overall benefit of statin usage 
regarding inflammatory response and general immunomodulation throughout the 
whole body, and hence, the synovial fluid in which RA develops. This has a very 
positive impact on atherosclerosis, because patients suffering with RA have an 
increased risk of developing endothelial inflammation, and hence, atherogenesis. 
Combining this data with the results of JUPITER study in CRP reduction, we can 
conclude that the anti-inflammatory and immunity modulating effects of statins could 
be very beneficial to developing RA. (34)
Alzheimer’s dementia (AD) is a disease characterized by gradual neuronal and 
synapse degeneration and that is why it is also stated as a neurodegenerative disorder.
This gradual neuronal loss leads to memory loss and cognitive impairment. The link 
between this disease and statins is cholesterol. Shepardson et al linked observational 
studies and Randomized Control Trials to conclude that there was a reduced risk of 
AD development in patients receiving statins compared to those not. However, the 
results suggested that the higher the patient’s age, the lesser the probability of a 
benefit from statin usage in memory loss because of AD. Despite the above 
mentioned facts, many of these studies were inconclusive and contained confusing 
results regarding statin benefit over AD complication development. (43,44,45)
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19 STATINS SIDE EFFECTS AND CONTRAINDICATIONS
Drug safety is one of the most important measures taken into account before 
administration. There are manydifferent vulnerable groups of people that the 
physician needs to be cautious with when prescribing medicine. Regarding statins, 
side effects usually include liver damage, myopathy, cognitive impairment (rarely), 
and an increased risk of developing pre-diabetes and diabetes in comparison with 
patients that are not on statins. 
Muscle pain is associated with their effect on Creatine Kinase (CK, also known 
as Creatine Phospokinase), an enzyme responsible for transferring a phosphate group 
for phosphocreatine to Adenosine Triphosphate (ATP).  Elevated levels of this 
enzyme in the blood can be used to diagnose muscle damage. The pain may be 
expanded and turn to myopathy, and in rare cases to rhabdomyolysis, a state in which 
muscle tissue is dissociated, leading to an excess in circulating myoglobin, a state 
which can cause serious glomerular injury and ultimately, kidney failure. Parker et al 
reported that there is a correlation between elevated physical exercise and statin 
induced myopathy. She describes that because during exercise muscle glycogen is 
reduced along with Adenosine Triphosphate (ATP), permeability of the muscle’s 
cellular membrane increases, a state that leads to muscular fiber dispersion and 
damage. In addition, Sakamoto et al suggested that statin induced myopathy is also 
related to GGPP depletion. We have already described the beneficial impact of GGPP 
depletion through HMG-CoA reductase inhibition in the development of 
atherosclerosis. However, other unwanted effects take place because of this depletion. 
GGPP is responsible for protein prenylation, and that seems to be involved in a 
complex pathway resulting in muscle cell apoptosis. Vulnerable groups include the 
elderly (especially women) in which muscle tissue is already in a smaller amount than 
healthy young people have. (46,47,48)
Glucose intolerance is one of the major health problems in developed countries. 
FDA (Food and Drug Administration) issued a warning in patients receiving statins in 
2012, concerning their effect on glucose tolerance. According to that warning, 
patients receiving statin treatment are more susceptible to develop type 2 diabetes and 
at the same time, patients already diagnosed with diabetes have an increased risk of 
glucose intolerance. The JUPITER study stated that there was an increase in incidence 
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of Diabetes Mellitus type II due to rosuvastatin usage. Sampson et al suggests that the 
JUPITER and WOSCOP (West of Scotland Coronary Prevention Study) trials 
provided us with insight on the risk of developing Diabetes Mellitus after statin usage. 
This insight suggests that the risk of developing DM after statin intervention increases 
slightly. However, the overall risk of developing CVD is greatly reduced with statins, 
because of their mechanism of action and pleiotropic effects, and according to 
Sampson et al the benefits of statin usage far outweigh the risk of DM development. 
(33,49)
Myopathy is an adverse effect that usually assists statin usage. Some other agents 
seem to potentiate and induce that effect by inhibiting the cytochrome isoform 
responsible for statin metabolism. They are thus contraindicated or used with caution 
with some agents (antifungal azole derivatives, macrolides, Cardio-depressive 
Calcium channel blockers, grapefruit juice). These effects are of high clinical 
significance especially with statins who are potent substrates for the CYP-450 (3A4) 
metabolizing pathway. One example of such a statin is simvastatin, which can exert 
increased muscular toxicity if co-administered with one or more of the agents 
mentioned above. (50,51)
Statins are also reported to cause mitochondrial defects. Because of the muscular 
tissue histophysiology, muscle fibers tend to be less dependent on mitochondrial 
defects when compared to other organs like the liver and kidneys. Non-muscular 
pathological conditions associated with statins, according to Golomb et al, may arise 
because of this effect statins in the mitochondrion. According to the tissue affected, 
adverse effects on a patient receiving statin therapy can be manifested as glucose 
elevation, insomnia and other psychological disturbances, encephalopathy (cognitive 
impairment), as well as Gastrointestinal and neurological abnormalities. These effects 
can be very risky especially in patients with co-morbidities. In severe cases,
hepatotoxicity and nephrotoxicity can be evident, and thus, statins are generally just 
used with caution in patients with chronic hepatic or renal insufficiency. (51)
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20 DEFINITION OF FIBRATES
Fibrates are agents derived from fibric acid and are widely used to normalize the 
lipid profile in both the human tissue and circulation. As Goldenberg et al pointed out, 
fibrates activate a receptor known as Peroxisome Proliferator Activated Receptor 
alpha (PPAR-α), which in turn binds to the Retinoid X Receptor alpha (RXR-α). A 
cascade pathway is responsible for specific gene transcription time alteration. Target 
genes are either increased or decreased, which ultimately increases or decreases their 
activity respectively. The major and most affected gene is called Lipoprotein Lipase
(LPL), which is responsible for TAG hydrolysis. Other genes affected by this 
mechanism affect HDL and LDL synthesis. Barter et al stated that these agents 
decrease TAG levels by up to 50% and increase HDL by up to 20%. However, their 
effect on LDL varies and can be both positively and negatively influenced. Examples 
of fibrates include Fenofibrate, Bezafirate and Gemfibrozil. (52,53)
Figure 4: The mechanism of action of fibrates, their binding to PPARα and its 
corresponding binding to RXR, actions that lead to gene transcription time 
modification, ultimately affecting many different pathways.
http://physrev.physiology.org/content/85/3/1093/F6.large.jpg 29/04/2015
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21 FIBRATE USAGE IN THE PREVENTION AND TREATMENT 
OF ATHEROSCLEROTIC ALTERATIONS
Fibrates are widely used to normalize altered lipid profiles since they affect many 
lipid producing pathways through their mechanism of action. Hypertriglyceridemia is 
a major risk factor for atherosclerosis development. The mechanism of action of 
fibrates, although complex, results in a modest decrease in TAG levels in the 
circulation. Through gene transcription time alteration, fibrates also diminish lipid 
production in muscular and hepatic tissue. The result is diminished VLDL (Very Low 
Density Lipoprotein) production, a precursor of LDL, which is well known as a major 
risk factor for atherosclerosis development. Their effects, however, on lipid profile are 
somewhat different from statins because of their different and indirect course of 
action. LDL and HDL levels are affected mostly positively, but they are not as evident 
as with statin treatment. As Tenenbaum et al states, fibrates are evident to decrease 
the risk of developing CVD complications due to atherogenic dyslipidemia, a state in 
which circulating TAG levels are elevated while HDL is decreased. (21)
As atherosclerotic pathophysiology is regarded, a lowering in TAG levels reduces 
the risk of complication development by diminishing the LDL available to be beta-
oxidized and create foam cells. (21)
It is clear nowadays that atherosclerosis is related to inflammatory response. 
Fibrates, and more specifically Fenofibrate, demonstrate pleiotropic effects like 
statins. The pathway by which they do so, however, is somewhat different from that 
of statins. Through their complex mechanism of action, as Moutzouri et al suggests 
,fibrates not only benefit lipid profile, but they are also evident to decrease many 
inflammatory response markers such as hs-CRP and Interleukin-6 (IL-6), both of 
which are associated atherosclerosis development. Other pleiotropic effects of fibrates
include fibrinogen, platelet aggregation and uric acid modulation, actions that are all 
significant in the correction of endothelial dysfunction (21,54)
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22 FIBRATES ADVERSE EFFECTS AND 
CONTRAINDICATIONS
Fibrates include various adverse drug reactions, most of which are mild. Nausea, 
Diarrhea, muscle pain and mild CK elevation are the most common among them. 
Other effects may include headaches, vertigo, insomnia and libido loss. However, 
fibrate treatment may result in elevated homocysteine, urea and creatinine levels, as 
well as a moderate decrease in Glomerular Filtration Rate (GFR). (54)
Usage with caution or contraindication when administering fibrates is usually 
with the following agents. Coumarin derivatives may be displaced and increase the 
risk of bleeding when used at the same time with Fenofibrate, since it is highly protein 
bound. Nephrotoxicity risk is multiplied when administering Fenofibrate with other 
nephrotoxic agents such as Cyclosporine and caution is advised when they are co-
administered. When hepatic or renal insufficiency is present, Fenofibrate is 
contraindicated. The most controversial issue so far, regarding contraindications, is 
co-administration of fibrates with statins. Fibrates seem to potentiate the muscular 
adverse effects of statins, especially with Gemfibrozil, since it is metabolized by the 
same enzyme metabolizing statins. (54)
23 POSSIBILITIES OF STATIN AND FIBRATE COMBINATION-
BENEFITS AND RISKS INCLUDED
Physicians have the possibility to prescribe more than one cholesterol decreasing 
agent according to the nature of the dyslipidemia. A patient with evident 
hypertriglyceridemia, decreased HDL and elevated LDL levels would normally not 
achieve maximum effect if treated with either statins or fibrates. However, when a 
statin is combined to a fibrate, they each have complementary effects on the lipid 
profile (see Figure 5). Fibrates are generally combined with statins when atherogenic 
dyslipidemia is evident, a state usual in patients suffering from DM. Since PPAR-
alpha activation involves more pathways than just regulating lipid profile, we can 
safely assume that they have pleiotropic effects like statins. Bezafibrate has a 
somewhat distinct mechanism of action in comparison with the other agents of this 
group. Letting aside its lipid normalizing potential, bezafibrate is also able to 
modulate and normalize glucose levels, since it acts as an agonist in all three PPAR 
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isoforms, namely alpha, gamma and delta. It is known that PPAR-gamma agonists are 
used to modulate glucose intolerance in patients with Type II DM. Since PPAR-
gamma is responsible for glucose regulation, the pleiotropic effect of bezafibrate and 
its concomitant PPAR-gamma agonistic effect is evident and beneficial in these 
patients. (21)




Fenofibric acid, a fibrate marketed as Trilipix, was found to be beneficial when 
combined with statins in decreasing CVD events up to 35%, especially in secondary 
prevention of atherosclerotic complications. Opposing the general rule, the 
combination of fenofibric acid and statins was not found to have adverse muscular, 
renal and hepatic effects. (18) 
As Agouridis et al clearly mentions, many studies including combination of 
different statins with fenofibrate were conducted in patients with DM suffering 
atherogenic mixed dyslipidemia, and the result was a decrease in LDL and TAG with 
the concomitant HDL increase. These resulting effects showed that these patients had
a decrease in the risk of developing CVD. Thus, a combination of these agents is 
beneficial when it comes to cases like this. The risk, however, of developing some 
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adverse effect is also increased, with the most clinically important one being myositis 
leading to rhabdomyolysis. (21,55)
Opposing this statin and fibrate combination-induced muscular adverse effect, 
however, studies such as FIELD (Fenofibrate Intervention and Event Lowering in 
Diabetes), ACCORD (Action to Control Cardiovascular Risk in Diabetes), as well as 
other sub-studies containing statin/fibrate combination, showed that there was a 
significant decrease in the risk of developing Type II DM induced morbidities. The 
results showed a decrease in the risk of developing microvascular retinopathy and 
necessity for laser intervention, nephropathy and albuminuria as well as DM induced 
limb amputation. (55)
There are other benefits included in the usage of statin/fibrate combination. 
PPARα activation is shown to activate many pleiotropic effects of statins. Balakumar 
et al explained that when statins are followed by PPAR activation, they have 
beneficial effect on arterial hypertension, inflammatory response, chemotherapy 
(carboplatin) induced nephrotoxicity, cyclooxygenase (COX) mediated aggregation, 
cardiac hypertrophy and fibrosis as well as urinary tract protecting effects against 
inflammation and fibrosis. Many of these effects, however, are still under preclinical 
studies and they are yet to be confirmed in humans. (56)
24 CONCLUSIONS
In our modern society, many bad habits such as sedentary lifestyle and lack of 
physical exercise, smoking, poor quality food consumption and alcohol abuse tend to 
lead to a gradual and silent building of risk factors of developing atherosclerosis over 
the years. CVD is becoming clearly the most threatening cause of morbidity and 
mortality in many countries, while in others it is already the leading cause of death. 
Due to pharmaceutical and medical breakthroughs accompanying the last 100 years, 
population aging is becoming more and more relevant to this CVD development. 
Until, however, an intervention slowing this process is developed, our focus remains 
on countering the risk factors of developing atherosclerosis and CVD, increasing the 
patient’s quality of life and reducing the risk of developing complications.
Atherosclerosis includes a wide range of risk factors and complications, and that 
is the main reason why more target-specific medicine becomes more and more 
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important. Many agents exert beneficial abilities on prevention and treatment of 
atherosclerosis. However, their impact is usually in one of the risk factors that may 
lead to it (Arterial Hypertension, Diabetes Mellitus, Dyslipidemia). 
Statins and Fibrates are agents suggesting an undeniably giant step in preventing 
and treating one of the major causes of atherosclerosis. With their potency on 
diminishing the levels of LDL cholesterol, statins provide a great resort for countering 
elevated LDL levels, which tend to oxidize when endothelial dysfunction is evident, 
leading to the formation of foam cells, and hence, development of atherosclerotic 
plaque. As most of the pharmaceutical agents, statins also have a number of adverse 
effects. In the recent years, interventions have been made to develop a statin capable 
of producing the same, if not more, diminishing effects on LDL, with a minimized 
expression of adverse drug reactions. Pitavastatin has shown a benefit on both those 
parameters, even when administered in a much lesser strength compared to other 
statins. Statins also exert pleiotropic effects, and this is their most significant 
difference among other pharmaceutical interventions against dyslipidemias. These 
beneficial effects are evident on inflammatory and aggregation response, on LDL 
beta-oxidation and on the vasculature (NO synthesis and expression). 
Fibrates is another class of lipid lowering interventions, acting through a different 
mechanism of action than that of statins. Atherogenic dyslipidemia is a common sight 
in patients with Type II DM, and it is characterized by diminished HDL levels, while 
free LDL and TAG levels in the circulation are elevated. Fibrates are effective on 
diminishing TAG through a gene expression inhibitory mechanism, while moderately 
increasing HDL. 
These effects are complementary to statins, and this is why combination of these 
2 classes is advised in cases like this. The risk of developing adverse effects due to 
monotherapy or combination of these agents must be always considered, especially in 
vulnerable patients suffering hepatic or renal insufficiency.  
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